Nicotinamide riboside chloride | CAS:23111-00-4

We serve Nicotinamide riboside chloride CAS:23111-00-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Nicotinamide riboside chloride

Chemical Name:Nicotinamide riboside chloride
CAS.NO:23111-00-4
Synonyms:Nicotinamide riboside chloride
Pyridinium, 3-​(aminocarbonyl)​-​1-​β-​D-​ribofuranosyl-​, chloride (1:1)
 
Physical and Chemical Properties:
Molecular Formula C11H15ClN2O5
Molecular Weight 290.70000
 
Description:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Use:Raw materials for food, health products.



Contact us for information like Nicotinamide riboside chloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyridinium, 3-​(aminocarbonyl)​-​1-​β-​D-​ribofuranosyl-​, chloride (1:1) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Nicotinamide riboside chloride Use and application,Nicotinamide riboside chloride technical grade,usp/ep/jp grade.


Related News: Chung also said South Korean citizens who had visited the province in the past 14 days should voluntarily quarantine themselves at home for two weeks after they arrive back into the country.1-Fluoro-6-iodohexane manufacturer Chung also said South Korean citizens who had visited the province in the past 14 days should voluntarily quarantine themselves at home for two weeks after they arrive back into the country.[dimethylamino-(2,5-dioxopyrrolidin-1-yl)oxymethylidene]-dimethylazanium,hexafluorophosphate supplier Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.Dibenzo[b,d]furan-1-ylboronic acid vendor “With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.”GlaxoSmithKline (GSK) is at the bottom of the top 20 list with the lowest percentage R&D spend/annual revenue at 12%.”